- Home
- VRN vs ACAD Comparison
VRN vs ACAD Comparison
Compare VRN & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRN
- ACAD
- Stock Information
- Founded
- VRN 1994
- ACAD 1993
- Country
- VRN Canada
- ACAD United States
- Employees
- VRN N/A
- ACAD N/A
- Industry
- VRN Oil & Gas Production
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- VRN Energy
- ACAD Health Care
- Exchange
- VRN Nasdaq
- ACAD Nasdaq
- Market Cap
- VRN 3.0B
- ACAD 3.4B
- IPO Year
- VRN N/A
- ACAD 2004
- Fundamental
- Price
- VRN $4.91
- ACAD $17.56
- Analyst Decision
- VRN Strong Buy
- ACAD Buy
- Analyst Count
- VRN 2
- ACAD 19
- Target Price
- VRN $11.50
- ACAD $25.33
- AVG Volume (30 Days)
- VRN 20.9M
- ACAD 1.8M
- Earning Date
- VRN 02-27-2025
- ACAD 05-07-2025
- Dividend Yield
- VRN 6.71%
- ACAD N/A
- EPS Growth
- VRN N/A
- ACAD N/A
- EPS
- VRN 0.31
- ACAD 1.36
- Revenue
- VRN $2,760,696,116.00
- ACAD $957,797,000.00
- Revenue This Year
- VRN $2.71
- ACAD $13.07
- Revenue Next Year
- VRN $1.67
- ACAD $9.97
- P/E Ratio
- VRN $15.80
- ACAD $12.91
- Revenue Growth
- VRN 24.52
- ACAD 31.85
- 52 Week Low
- VRN $4.39
- ACAD $14.15
- 52 Week High
- VRN $9.28
- ACAD $24.27
- Technical
- Relative Strength Index (RSI)
- VRN 44.29
- ACAD 38.70
- Support Level
- VRN $4.68
- ACAD $17.85
- Resistance Level
- VRN $5.54
- ACAD $19.69
- Average True Range (ATR)
- VRN 0.25
- ACAD 0.80
- MACD
- VRN -0.02
- ACAD -0.28
- Stochastic Oscillator
- VRN 26.74
- ACAD 6.87
About VRN Veren Inc. Common shares
Veren Inc is an oil producer company. It is engaged in acquiring, developing, and holding interests in petroleum assets operations across western Canada.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.